← Leaderboards
Wolfgang Singer
Mayo Clinic Rochester
$6,707,804
Attributed
$10,111,679
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,934,723 · 2
FDA$3,176,956 · 1
By mechanism
R01$9,239,476 · 2
K23$872,203 · 1
Top collaborators
- Prashanthi Vemuri5 shared
- Clifford Jack4 shared
- Phillip A Low4 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Howard J Rosen$46,265,858
- Prashanthi Vemuri$20,262,102
- Praveen Dayalu$1,285,035
- Adam L Boxer$75,127,044
- Pamela J McCabe$402,384
Others in their field
Top investigators on “Laboratories”
- David Heimbrook · Leidos Biomedical Research, Inc.$943,075,715
- Lawrence Corey · Fred Hutchinson Cancer Center$747,603,944
- Jeffrey P Krischer · University Of South Florida$627,303,958
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$553,634,937
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$463,311,620
Research focus
LaboratoriesFunctional DisorderPatternPhenotypeBaseCategoriesPositioning AttributeFailureInstitutionFutureCollaborationsSymptomsDiagnosisAlpha SynucleinMotorMagnetic Resonance ImagingDatabasesMorphometryMotor SymptomBiological MarkersImageCohortCerebrospinal FluidEarly Diagnosis
Grant awards (18)
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,340
R01 · FY2025 · NS · contact PI
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial of Intrathecally Administered Autologous Mesenchymal Stem Cells in Multiple System Atrophy$792,634
R01 · FY2024 · FD · contact PI
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,340
R01 · FY2024 · NS · contact PI
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial of Intrathecally Administered Autologous Mesenchymal Stem Cells in Multiple System Atrophy$792,634
R01 · FY2023 · FD · contact PI
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,340
R01 · FY2023 · NS · contact PI
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial of Intrathecally Administered Autologous Mesenchymal Stem Cells in Multiple System Atrophy$792,634
R01 · FY2022 · FD · contact PI
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,405
R01 · FY2022 · NS · contact PI
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial of Intrathecally Administered Autologous Mesenchymal Stem Cells in Multiple System Atrophy$799,054
R01 · FY2021 · FD · contact PI
Synucleinopathies â Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$765,405
R01 · FY2021 · NS · contact PI
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$575,041
R01 · FY2019 · NS
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$559,929
R01 · FY2018 · NS
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$561,241
R01 · FY2017 · NS
Multiple System Atrophy - Novel Targets in Early Diagnosis, Pathophysiology, and Therapeutic Approach$539,479
R01 · FY2016 · NS
Differential Approach to the Postural Tachycardia Syndrome$176,466
K23 · FY2016 · NS · contact PI
Differential Approach to the Postural Tachycardia Syndrome$176,082
K23 · FY2015 · NS · contact PI
Differential Approach to the Postural Tachycardia Syndrome$176,539
K23 · FY2014 · NS · contact PI
Differential Approach to the Postural Tachycardia Syndrome$177,524
K23 · FY2013 · NS · contact PI
Differential Approach to the Postural Tachycardia Syndrome$165,592
K23 · FY2012 · NS · contact PI